Dopaminergic Modulation of Medial Prefrontal Cortex Deactivation in Parkinson Depression.

Dopaminergic Modulation of Medial Prefrontal Cortex Deactivation in Parkinson Depression.
复制标题

DOI:
10.1155/2015/513452
复制
发表时间:
2015
期刊:
Parkinson's disease
影响因子:
--
通讯作者:
Blonder LX
Blonder LX
中科院分区:
其他
文献类型:
--
作者:
Andersen AH;Smith CD;Slevin JT;Kryscio RJ;Martin CA;Schmitt FA;Blonder LX

文献摘要

被引文献

相似文献

帕金森病(PD)与情绪异常有关。多巴胺能药物可以改善帕金森病的运动症状,但是关于多巴胺能药物对情感处理的影响,特别是在抑郁性PD(dPD)患者中,人们知之甚少。本研究的目的是研究多巴胺能药物治疗对抑郁与非抑郁帕金森病(ndPD)患者大脑激活情绪刺激的影响。参与者包括18名ndPD患者(11名男性,7名女性)和10名dPD患者(7名男性,3名女性)。患者在功能性磁共振成像中观看情绪化面孔的照片。扫描是在患者服用抗帕金森药物时进行的,并在药物暂时停药后的第二天进行。结果表明,多巴胺能药物在前额叶皮层有相反的影响,这取决于抑郁状态。DPD患者在多巴胺能药物治疗时的腹内侧前额叶皮层(VMPFC)表现出更大的失活,而ndPD患者在该区域表现出更大的失活。VMPFC位于默认模式网络(DMN)中。DMN活动与用于外部视觉注意的大脑系统的活动呈负相关。因此,多巴胺能药物可能会促进dPD患者对外部视觉刺激的注意力增加,但会阻碍ndPD患者在外部刺激期间对DMN活性的正常抑制。
Parkinson's disease (PD) is associated with emotional abnormalities. Dopaminergic medications ameliorate Parkinsonian motor symptoms, but less is known regarding the impact of dopaminergic agents on affective processing, particularly in depressed PD (dPD) patients. The aim of this study was to examine the effects of dopaminergic pharmacotherapy on brain activation to emotional stimuli in depressed versus nondepressed Parkinson disease (ndPD) patients. Participants included 18 ndPD patients (11 men, 7 women) and 10 dPD patients (7 men, 3 women). Patients viewed photographs of emotional faces during functional MRI. Scans were performed while the patient was taking anti-Parkinson medication and the day after medication had been temporarily discontinued. Results indicate that dopaminergic medications have opposite effects in the prefrontal cortex depending upon depression status. DPD patients show greater deactivation in the ventromedial prefrontal cortex (VMPFC) on dopaminergic medications than off, while ndPD patients show greater deactivation in this region off drugs. The VMPFC is in the default-mode network (DMN). DMN activity is negatively correlated with activity in brain systems used for external visual attention. Thus dopaminergic medications may promote increased attention to external visual stimuli among dPD patients but impede normal suppression of DMN activity during external stimulation among ndPD patients.